Pertussis cost-effectiveness of therapy: Difference between revisions
Ochuko Ajari (talk | contribs) No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
The morbidity and societal cost of pertussis in adults is substantial. A retrospective assessment of medical costs of confirmed pertussis in 936 adults in Massachusetts during 1998 to 2000, and a prospective assessment of nonmedical costs in 203 adults during 2001 to 2003 indicated that the mean medical and nonmedical cost per case was $326 and $447, respectively, for a societal cost of $773. If the cost of antimicrobials to treat contacts and the cost of personal time were included, the societal cost could be as high as $1,952 per adult case.<ref name="urlNational Guideline Clearinghouse | Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP).">{{cite web |url=http://guideline.gov/content.aspx?id=12632 |title=National Guideline Clearinghouse | Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP). |format= |work= |accessdate=}}</ref> | The morbidity and societal cost of pertussis in adults is substantial. A retrospective assessment of medical costs of confirmed pertussis in 936 adults in Massachusetts during 1998 to 2000, and a prospective assessment of nonmedical costs in 203 adults during 2001 to 2003 indicated that the mean medical and nonmedical cost per case was $326 and $447, respectively, for a societal cost of $773. If the cost of antimicrobials to treat contacts and the cost of personal time were included, the societal cost could be as high as $1,952 per adult case.<ref name="urlNational Guideline Clearinghouse | Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP).">{{cite web |url=http://guideline.gov/content.aspx?id=12632 |title=National Guideline Clearinghouse | Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP). |format= |work= |accessdate=}}</ref> | ||
==Cost Effectiveness of Vaccination== | ===Cost Effectiveness of Vaccination=== | ||
Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved. | Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved. | ||
Revision as of 19:40, 4 April 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
|
Pertussis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pertussis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Pertussis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Pertussis cost-effectiveness of therapy |
Cost Effectiveness of Therapy
The morbidity and societal cost of pertussis in adults is substantial. A retrospective assessment of medical costs of confirmed pertussis in 936 adults in Massachusetts during 1998 to 2000, and a prospective assessment of nonmedical costs in 203 adults during 2001 to 2003 indicated that the mean medical and nonmedical cost per case was $326 and $447, respectively, for a societal cost of $773. If the cost of antimicrobials to treat contacts and the cost of personal time were included, the societal cost could be as high as $1,952 per adult case.[1]
Cost Effectiveness of Vaccination
Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved.